Memantine in the Treatment of Kleptomania

• Status: Completed
• Trial end date: 2012-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of the proposed study is to evaluate the efficacy and safety of memantine in kleptomania.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Chicago
• Treatments: Memantine

Criteria

Inclusion Criteria:

1. men and women age 18-65

2. current KM using the clinician-administered Structured Clinical Interview for Kleptomania (SCI-K)

3. stealing behavior within 2 weeks prior to enrollment.

Exclusion Criteria:

1. infrequent stealing (i.e. less than one time per week) that does not meet proposed criteria for kleptomania (KM)

2. unstable medical illness or clinically significant abnormalities on laboratory tests or physical examination at screen

3. history of seizures

4. myocardial infarction within 6 months

5. current pregnancy or lactation, or inadequate contraception in women of childbearing potential

6. a need for medication other than memantine with possible psychotropic effects or unfavorable interactions

7. clinically significant suicidality

8. current Axis I disorder determined by the Structured Clinical Interview for the DSM (SCID) and SCID-compatible modules for impulse control disorders (Grant et al., 2005), except for nicotine dependence

9. lifetime history of bipolar disorder type I or II, dementia, schizophrenia, or any psychotic disorder determined by SCID

10. current or recent (past 3 months) DSM-IV substance abuse or dependence

11. positive urine drug screen at screening

12. initiation of psychotherapy or behavior therapy within 3 months prior to study baseline

13. previous treatment with memantine; and 14) treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline.